文献速递白血病

menin与MEK联合抑制靶向不良预后KMT2A重排伴RAS通路突变急性髓系白血病

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

该临床前研究基于儿童肿瘤协作组1750例患者数据,发现43%的AML携带RAS通路突变,KMT2A重排AML中RAS突变与较低完全缓解率、较差无事件生存和总生存及早期复发相关。研究评估MEK1/2抑制剂selumetinib联合menin抑制剂revumenib,在细胞系和PDX模型中出现协同活性,但在体内仅降低白血病负荷而未改善总生存。

要点

  • KMT2A重排AML中RAS通路突变发生率高且与不良预后相关。
  • selumetinib联合revumenib在体外呈协同抗白血病作用。
  • 体内联合治疗降低白血病负荷但未优于单药menin抑制的总生存。

核心结论

  • menin与MEK联合抑制是KMT2A重排伴RAS通路突变白血病的潜在靶向组合,但需进一步优化。

研究设计与样本

  • 研究为临床前研究,基于儿童肿瘤协作组(COG)1750例入组患者的队列分析。
  • 体外使用AML细胞系和患者来源异种移植(PDX)模型培养的白血病细胞。
  • 体内使用携带KMT2A重排和RAS突变的儿童AML PDX模型。

主要发现

  • 在1750例COG试验入组患者中,43%的急性髓系白血病(AML)病例携带RAS通路突变。
  • KMT2A重排AML中RAS通路突变与较低完全缓解率、较差无事件生存和总生存(OS)及早期复发相关。
  • 联合治疗在体外较单药协同降低活力,并促进细胞周期阻滞、凋亡及Myc靶基因下调。
  • 体内联合治疗较单药降低白血病负荷,但相较单药menin抑制未改善OS。

临床怎么用

  • 该联合方案尚属临床前探索,暂不能直接用于临床决策。
  • 对KMT2A重排伴RAS通路突变AML可考虑开展进一步优化和转化研究。

局限性

  • 为临床前研究,体内联合治疗未改善OS,需进一步优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KMT2A-rearranged (KMT2A-r) acute leukemias are especially prevalent in the pediatric population. KMT2A-fusion proteins drive leukemogenic gene expression through an interaction with a chromatin complex that includes the scaffold protein menin, giving rise to aggressive acute leukemias. RAS pathway mutations are also common in pediatric leukemia. In a cohort of 1750 patients enrolled on Children's Oncology Group (COG) trials, we identified RAS pathway mutations in 43% of acute myeloid leukemia (AML) cases. The presence of RAS pathway mutations in KMT2A-r AML was associated with a lower complete remission rate, poor event-free survival and overall survival (OS), and early relapses. Given the inferior outcome observed for children with dual mutations, we next sought to identify efficacious targeted drug combinations for this subset of childhood leukemia. We evaluated RAS/MAPK targeting using the MEK1/2 inhibitor selumetinib in combination with the menin inhibitor revumenib. Treatment of AML cell lines and cultured leukemia cells from patient-derived xenograft (PDX) models resulted in a synergistic decrease in viability and promoted cell cycle arrest, apoptosis, and downregulation of Myc targets in the combination compared with each drug alone. In vivo, the combination treatment of AML pediatric PDX models harboring KMT2A-r and RAS mutations reduced leukemia burden compared with single-drug treatments but without improving OS compared with menin inhibition alone. Our preclinical study suggests a potential targeted treatment combination for KMT2A-r and RAS pathway-mutant leukemia but one that will require further optimization. These trials were registered at www.clinicaltrials.gov as NCT00070174, NCT00372593, NCT01371981, and NCT00002798.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Scheidegger N, Schneider C, Alexe G, et al. Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia. Blood Adv. 2026. PMID: 42085603. doi:10.1182/bloodadvances.2025016208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。